TriSalus Life Sciences (NASDAQ:TLSI) Announces Quarterly Earnings Results

TriSalus Life Sciences (NASDAQ:TLSI) released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01, Zacks reports. The business had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• TriSalus reported strong results with Q4 revenue of $13.2M and full-year revenue of $45.2M (up 60% and 53% YoY) while improving gross margin and materially narrowing adjusted EBITDA loss, and it achieved its 2025 revenue guidance.
• The company completed a more-than-2x-oversubscribed public offering in February, raising $46 million in gross proceeds to fund commercial expansion, clinical evidence generation, and product innovation.
• Management is virtually doubling the commercial footprint and expanding the TriNav portfolio to seven offerings (including the anticipated H1 2026 launch of TriNav Advance), reaffirmed 2026 revenue guidance of $60–62M, and expects H2-weighted growth as new hires are onboarded and new products scale.
• The company delayed release of consolidated Phase 1 data for nelitolimod to H2 2026 to create a more complete data package for partners and has substantially reduced internal development spending, which could defer near-term partnership progress or value realization.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $4.08 on Tuesday. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $7.95. The stock has a market capitalization of $250.13 million, a price-to-earnings ratio of -2.23 and a beta of 0.54. The stock’s fifty day moving average is $4.56 and its two-hundred day moving average is $5.23.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 6th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Hold” and a consensus target price of $7.00.

Insider Activity

In other news, CEO Mary T. Szela sold 15,944 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.85, for a total value of $61,384.40. Following the completion of the sale, the chief executive officer owned 752,987 shares of the company’s stock, valued at $2,898,999.95. This trade represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 30,150 shares of company stock valued at $119,849 in the last ninety days. 27.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of hedge funds have recently bought and sold shares of TLSI. State Street Corp raised its position in shares of TriSalus Life Sciences by 37.4% during the fourth quarter. State Street Corp now owns 264,628 shares of the company’s stock valued at $1,847,000 after buying an additional 71,995 shares during the last quarter. Bank of America Corp DE lifted its holdings in TriSalus Life Sciences by 1.8% during the 2nd quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock worth $1,030,000 after purchasing an additional 3,374 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of TriSalus Life Sciences by 74.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 100,077 shares of the company’s stock worth $699,000 after acquiring an additional 42,772 shares during the period. Empire Financial Management Company LLC bought a new position in TriSalus Life Sciences in the fourth quarter valued at about $503,000. Finally, Squarepoint Ops LLC bought a new position in TriSalus Life Sciences during the third quarter worth $343,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.